<DOC>
	<DOCNO>NCT02321267</DOCNO>
	<brief_summary>Macular disease often case severe visual impairment . Recent clinical introduction anti-vascular endothelial growth factor agent may change clinical course various macular disease , include age-related macular degeneration ( AMD ) , polypoidal choroidal vasculopathy ( PCV ) , retinal angiomatous proliferation ( RAP ) , central serous chorioretinopathy ( CSC ) , myopic choroidal neovascularization ( CNV ) , retinal vein occlusion ( RVO ) , diabetic macular edema ( DME ) , forth . The advance vitrectomy improve visual outcome maculae disease , include epiretinal membrane ( ERM ) , macular hole ( MH ) , vitreomacular traction syndrome ( VMTS ) . Patients macular disease register follow 5 year appropriate treatment patient . By analysis correlation initial examination final visual acuity , factor associate good visual prognosis elucidate .</brief_summary>
	<brief_title>Cohort Study Clinical Course Macular Diseases Kagawa</brief_title>
	<detailed_description />
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>Patients visit Department Ophthalmology , Kagawa University Hospital macular disease , AMD , PCV , RAP , RVO , DME , ERM , MH , VMTS . Patients agree participation study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>AMD</keyword>
	<keyword>PCV</keyword>
	<keyword>RAP</keyword>
	<keyword>RVO</keyword>
	<keyword>DME</keyword>
	<keyword>ERM</keyword>
	<keyword>MH</keyword>
	<keyword>mCNV</keyword>
</DOC>